Spectrum Has A Rosy Glow
When Spectrum Pharmaceuticals (SPPI ) (SPPI) announced on Sept. 25 that results from the Phase 3 trials of its Satraplatin were "positive," its shares bolted from 3.49 to 5 in a day--and are now at 5.34. Satraplatin is platinum-based chemotherapy taken orally for hormone-resistant prostate cancer. After the stock's jump, some warn there may be limited room to run. Not so, says Ren Benjamin of Rodman & Renshaw, who rates it "outperform," with a 12-month target of 13. Based on early results and the timeline for accelerated approval, he says, Satraplatin may be launched in the U.S. in the third quarter of 2007. Assuming world sales of $500 million a year, Benjamin figures Spectrum's royalties from partners GPC Biotech and Pharmion (PHRM ) will total $50 million by 2012. But he says the price doesn't yet reflect Spectrum's other products, such as Ozarelix for enlarged prostates. On Oct. 2, Spectrum announced that Phase 2 trials for Ozarelix were "significantly positive." The trials, held in Europe with partner Æ terna Zentaris, had "an excellent safety profile" in treating benign prostatic hypertrophy, says CEO Rajesh Shrotriya. Megan Murphy of Lazard Capital Markets, who rates Spectrum a "buy," has a 12-month price target of 10.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.
By Gene G. Marcial